Showing results (61-70 of 118) with videos related to
Sort By:
Pageof 12
The British Journal of Radiology|February 5, 2021
Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue typesSarah Denzler, Diem Vuong, Marta Bogowicz, et al.Frontiers in Oncology|July 12, 2021
In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the TorsoRoni Blatt, Shiri Davidi, Mijal Munster, et al.Seminars in Oncology|September 13, 2014
Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivoMoshe Giladi, Uri Weinberg, Rosa S Schneiderman, et al.Cancer Chemotherapy and Pharmacology|August 25, 2019
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN studySacha I Rothschild, Daniel Betticher, Reinhard Zenhäusern, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, et al.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 9, 2017
Using computational phantoms to improve delivery of Tumor Treating Fields (TTFields) to patientsZe'ev Bomzon, Hadas Sara Hershkovich, Noa Urman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2015
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, et al.Cell Death & Disease|October 21, 2018
AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)Anna Shteingauz, Yaara Porat, Tali Voloshin, et al.Journal of Visualized Experiments : Jove|May 19, 2017
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)Yaara Porat, Moshe Giladi, Rosa S Schneiderman, et al.Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.Pageof 12